SCHEMBL204153

SCHEMBL204153

Nc1cnc2cccnc2c1N

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.44
HSP90AA1 P07900 5/20 0.42
LMNA P02545 4/20 0.42
MAPT P10636 4/20 0.42
HSP90AB1 P08238 3/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
HTT P42858 2/20 0.42
HIF1A Q16665 2/20 0.42
BLM P54132 1/20 0.42
PRMT5 O14744 1/20 0.42
IDO1 P14902 1/20 0.40
PSMB5 P28074 1/20 0.40
ALDH1A1 P00352 3/20 0.39
APAF1 O14727 1/20 0.39
TDP2 O95551 1/20 0.39
CASP3 P42574 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL202822 0.80 KDM4E (0.42) KDM4EHSP90AA1LMNAMAPTHSP90AB1
SCHEMBL22587674 0.80 KDM4E (0.42) KDM4EHSP90AA1LMNAMAPTHSP90AB1
SCHEMBL31330029 0.80 MEN1 (0.44) KDM4EHSP90AA1LMNAMAPTHSP90AB1
SCHEMBL2706312 0.80 HSP90AA1 (0.58) KDM4EHSP90AA1LMNAMAPTHSP90AB1
SCHEMBL22595963 0.80 PRMT5 (0.47) KDM4EHSP90AA1LMNAMAPTHSP90AB1
SCHEMBL22595525 0.76 PRMT5 (0.40) KDM4EHSP90AA1LMNAMAPTHSP90AB1
SCHEMBL29288471 0.76 PRMT5 (0.40) KDM4EHSP90AA1LMNAMAPTHSP90AB1
SCHEMBL22587675 0.74 PRMT5 (0.39) KDM4EHSP90AA1LMNAMAPTHSP90AB1
SCHEMBL5259859 0.74 NAPRT (0.51) KDM4ELMNAMAPTMEN1KMT2A
SCHEMBL29531848 0.74 KDM4E (0.41) KDM4EHSP90AA1LMNAMAPTHSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8658666-B2 Substituted imidazoquinolines and imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2014-02-25 US disclosed
US-8546383-B2 Chiral fused [1,2]imidazo[4,5-c] ring compounds 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-10-01 US disclosed
US-8350034-B2 Substituted chiral fused [1,2]imidazo[4,5-C] ring compounds 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-01-08 US disclosed
US-8329721-B2 Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-12-11 US disclosed
US-20120232057-A1 CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS 3M INNOVATIVE PROPERTIES COMPANY 2012-09-13 US disclosed
EP-1831221-B1 SUBSTITUTED CHIRAL FUSED 1,2 IMIDAZO 4,5-C RING COMPOUNDS 3M INNOVATIVE PROPERTIES CO (US) 2012-08-08 EP disclosed
EP-1831226-B1 CHIRAL TETRACYCLIC COMPOUNDS INDUCING INTERFERON BIOSYNTHESIS 3M INNOVATIVE PROPERTIES CO (US) 2012-08-08 EP disclosed
US-8207162-B2 Chiral fused [1,2]imidazo[4,5-c] ring compounds 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-06-26 US disclosed
US-8178539-B2 Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-05-15 US disclosed
US-8143270-B2 2-amino 1H-in-imidazo ring systems and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-03-27 US disclosed
US-20030096998-A1 Imidazonaphtyridines 3M INNOVATIVE PROPERTIES COMPANY 2003-05-22 US disclosed
US-20030083500-A1 Imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY 2003-05-01 US disclosed
US-6518280-B2 Antiviral and antitumor properties; immunomodulators and for inducing cytokine biosynthesis in animals 3M INNOVATIVE PROPERTIES COMPANY 2003-02-11 US disclosed
US-6514985-B1 Induce the biosynthesis of cytokines such as interferon and tumor necrosis factor; exhibit antiviral and antitumor properties 3M INNOVATIVE PROPERTIES COMPANY 2003-02-04 US disclosed
US-20020173654-A1 Imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY 2002-11-21 US disclosed
US-20020173653-A1 Imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY 2002-11-21 US disclosed
US-6194425-B1 VIRICIDES, ANTITUMOR AGENTS 3M INNOVATIVE PROPERTIES COMPANY 2001-02-27 US disclosed
CN-1284957-A Imidazonaphthyridines and their use in inducing cytokine biosynthesis MINNESOTA MINING & MFG (US) 2001-02-21 CN disclosed
EP-1040112-A1 IMIDAZONAPHTHYRIDINES AND THEIR USE IN INDUCING CYTOKINE BIOSYNTHESIS MINNESOTA MINING AND MANUFACTURING COMPANY (US) 2000-10-04 EP disclosed
WO-1999029693-A1 IMIDAZONAPHTHYRIDINES AND THEIR USE IN INDUCING CYTOKINE BIOSYNTHESIS MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1999-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083500-A1 Imidazonaphthyridines IFNG, IRF3, IFNAR1 KDM4E 4437/4885HSP90AA1 2193/4885LMNA 3209/4885
US-20030096998-A1 Imidazonaphtyridines IFNG, IRF3, IFNAR1 KDM4E 4492/4885HSP90AA1 2222/4885LMNA 3119/4885
US-20120232057-A1 CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS IFNAR1, IFNG, IL4 KDM4E 3075/4885HSP90AA1 3450/4885LMNA 2497/4885
US-20020173653-A1 Imidazonaphthyridines IFNG, IRF3, IFNAR1 KDM4E 4437/4885HSP90AA1 2193/4885LMNA 3209/4885
US-20020173654-A1 Imidazonaphthyridines IFNG, IRF3, IFNAR1 KDM4E 4437/4885HSP90AA1 2193/4885LMNA 3209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.